A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

807

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Lyme Disease
Interventions
BIOLOGICAL

mRNA-1975

Dispersion delivered IM

BIOLOGICAL

mRNA-1982

Dispersion delivered IM

BIOLOGICAL

Placebo

Solution delivered IM

Trial Locations (20)

14609

Rochester Clinical Research, Inc., Rochester

19040

Hatboro Medical Associates/CCT Research, Hatboro

20850

Advanced Primary and Geriatric Care, Rockville

21045

Centennial Medical Group, Columbia

22911

Charlottesville Medical Research Center, LLC, Charlottesville

30281

Clinical Research Atlanta, headlands LLC, Stockbridge

32216

Encore Research Group-Jacksonville Center for Clinical Research, Jacksonville

32746

University Clinical Research-DeLand, LLC d/b/a Accel Research Sites, Lake Mary

55402

Clinical Research Institute, Inc., Minneapolis

66219

Johnson County Clin-Trials, Inc. (JCCT), Lenexa

68134

Meridian Clinical Research - Omaha, Omaha

73112

Lynn Health Science Institute, Oklahoma City

76135

Benchmark Research, Fort Worth

77375

DM Clinical Research, Tomball

06460

Clinical Research Consulting, LLC, Milford

06905

Stamford Therapeutics Consortium, Stamford

06708

Chase Medical Research, LLC, Waterbury

02445

DM Clinical Research - Brookline, Brookline

03801

ActivMed Research LLC, Newington

02886

Velocity Clinical Research Providence, Providence

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY